Ovarian function measures in normogonadotropic anovulation and subclinical thyroid dysfunction: a prospective cohort study.

IF 3.7 3区医学 Q2 Medicine

Endocrine Pub Date : 2025-01-02 DOI:10.1007/s12020-024-04151-1

Iwona Gawron, Rafal Baran, Robert Jach

{"title":"Ovarian function measures in normogonadotropic anovulation and subclinical thyroid dysfunction: a prospective cohort study.","authors":"Iwona Gawron, Rafal Baran, Robert Jach","doi":"10.1007/s12020-024-04151-1","DOIUrl":null,"url":null,"abstract":"Purpose: To compare ovarian function measures in euthyroid women with normogonadotropic anovulation in subclinical hypothyroidism (SCH) or thyroid autoimmunity (TAI) to those without thyroid dysfunction.Design: A prospective open-label cohort study analyzed anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone, estradiol and testosterone concentrations, ovarian volume, and polycystic ovarian morphology (PCOM) incidence between women with and without SCH or TAI in two study arms: polycystic ovary syndrome (PCOS) and hypothalamic-pituitary-ovarian dysfunction (HPOD).Results: The prevalence of circulating thyroid peroxidase antibodies (TPOAb) was higher in the PCOS compared to the HPOD arm (p = 0.006). No significant differences in the measured parameters were observed based on SCH or TAI status across the entire cohort or individual study arms, except for phenotype D of PCOS, where a greater volume (p = 0.031) and higher incidence of physiological lesions (p = 0.047) in the left ovary were noted in SCH, and phenotype A, where LH concentrations (p = 0.038) were significantly higher in women without TAI. In the PCOS arm, thyroglobulin antibodies (TGAb) concentration correlated negatively with FSH (p = 0.049) and positively with testosterone (p = 0.012) concentrations, while in the HPOD arm, TPOAb and FSH concentrations were negatively correlated (p = 0.028).Conclusions: No clinically significant impact of SCH on ovarian function measures was demonstrated. Regarding TAI, significant correlations with still uncertain clinical significance were observed with FSH concentrations, both in PCOS and in HPOD. In view of the obtained results, the benefits of thyroxine supplementation to address menstrual irregularities and improve obstetric outcomes in the examined conditions, require support with clinical evidence.","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-024-04151-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare ovarian function measures in euthyroid women with normogonadotropic anovulation in subclinical hypothyroidism (SCH) or thyroid autoimmunity (TAI) to those without thyroid dysfunction.

Design: A prospective open-label cohort study analyzed anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone, estradiol and testosterone concentrations, ovarian volume, and polycystic ovarian morphology (PCOM) incidence between women with and without SCH or TAI in two study arms: polycystic ovary syndrome (PCOS) and hypothalamic-pituitary-ovarian dysfunction (HPOD).

Results: The prevalence of circulating thyroid peroxidase antibodies (TPOAb) was higher in the PCOS compared to the HPOD arm (p = 0.006). No significant differences in the measured parameters were observed based on SCH or TAI status across the entire cohort or individual study arms, except for phenotype D of PCOS, where a greater volume (p = 0.031) and higher incidence of physiological lesions (p = 0.047) in the left ovary were noted in SCH, and phenotype A, where LH concentrations (p = 0.038) were significantly higher in women without TAI. In the PCOS arm, thyroglobulin antibodies (TGAb) concentration correlated negatively with FSH (p = 0.049) and positively with testosterone (p = 0.012) concentrations, while in the HPOD arm, TPOAb and FSH concentrations were negatively correlated (p = 0.028).

Conclusions: No clinically significant impact of SCH on ovarian function measures was demonstrated. Regarding TAI, significant correlations with still uncertain clinical significance were observed with FSH concentrations, both in PCOS and in HPOD. In view of the obtained results, the benefits of thyroxine supplementation to address menstrual irregularities and improve obstetric outcomes in the examined conditions, require support with clinical evidence.

查看原文本刊更多论文

促性腺激素正常无排卵和亚临床甲状腺功能障碍的卵巢功能测量：一项前瞻性队列研究。

目的：比较亚临床甲状腺功能减退症（SCH）或甲状腺自身免疫（TAI）患者与无甲状腺功能障碍的正常促性腺激素无排卵的甲状腺功能正常妇女的卵巢功能。设计：一项前瞻性开放标签队列研究分析了在多囊卵巢综合征（PCOS）和下丘脑-垂体-卵巢功能障碍（HPOD）两个研究组中，有和没有SCH或TAI的女性的抗勒勒激素（AMH）、促卵泡激素（FSH）、促黄体生成素、雌二醇和睾酮浓度、卵巢体积和多囊卵巢形态（PCOM）发生率。结果：PCOS组循环甲状腺过氧化物酶抗体（TPOAb）的流行率高于HPOD组（p = 0.006）。在整个队列或单个研究组中，基于SCH或TAI状态的测量参数没有观察到显著差异，但PCOS的表型D中，SCH的左卵巢体积更大（p = 0.031），生理病变发生率更高（p = 0.047），而表型a中，LH浓度（p = 0.038）在没有TAI的女性中显着更高。在PCOS组，甲状腺球蛋白抗体（TGAb）浓度与FSH呈负相关（p = 0.049），与睾酮呈正相关（p = 0.012），而在HPOD组，TPOAb和FSH浓度呈负相关（p = 0.028）。结论：未发现SCH对卵巢功能指标有显著影响。至于TAI，在PCOS和HPOD中，FSH浓度与PCOS和HPOD均有显著相关性，但临床意义尚不确定。鉴于已获得的结果，补充甲状腺素对解决月经不规律和改善检查条件下的产科结果的益处需要临床证据的支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine 医学-内分泌学与代谢

CiteScore

6.40

自引率

5.40%

发文量

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.